The company plans to add 1700 beds by FY27 through the organic route
International Business is expected to register double-digit growth in constant currency terms
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
New leadership team announced at NATHEALTH Annual General Meeting 2024
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
This acquisition enables MTD to open new, strategic markets
Subscribe To Our Newsletter & Stay Updated